Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. (PROMETEY)
-
- STATUS
- Recruiting
-
- End date
- Jun 28, 2024
-
- participants needed
- 500
-
- sponsor
- Moscow State University of Medicine and Dentistry
Summary
Advances in treatment have led to improved survival of patients with cancer, but have also increased morbidity and mortality due to cancer treatment side effects. Cardiotoxicity is one the most frequent side effect which may lead to premature morbidity and death among cancer survivors. The most concerning cardiovascular complications of cancer therapy is myocardial dysfunction, leading to heart failure, and fatal arrhythmias, especially those induced by QT-prolonging drugs.
PROMETEY (PROspective Multidisciplinary obsErvational Trial of cardiotoxicity in patiEnts undergoing anticancer therapy) - is Russian multicenter observational study assessing cardiotoxicity and its clinical, biochemical and genetic factors in patients on cancer therapy.
The objectives of the study are:
- to reveal prevalence of cardiotoxic effects of cancer therapy in routine clinical practice in Russian Federation,
- to assess contribution of these effects to mortality of patients on cancer therapy,
- to evaluate clinical and economic consequences of cardiotoxicity in patients with cancer,
- to develop an individualized model of cardiotoxicity risk factors based on clinical and laboratory parameters.
Patients: 400 cancer patients with toxic cardiomyopathy and 100 patients with idiopathic or family dilated cardiomyopathy.
Study duration: 60 months. All patients will undergo complex examination after signing informed consent form(ICF): physical exam, echocardiography with speckle tracking analysis, ambulatory 48-hours ECG monitoring, biochemistry, analysis of biomarkers of myocardial injury, fibrosis and inflammation.
Primary endpoint: all-cause mortality, heart transplantation, cardioverter-defibrillator implantation, hospitalization with heart failure decompensation.
Secondary endpoints:
- thromboembolism,
- fatal/ nonfatal myocardial infarction, stroke,
- sudden cardiac death,
- surgical therapy of heart failure or arrhythmias,
- cardiovascular death,
- all-cause mortality,
- heart transplantation,
- cardioverter-defibrillator implantation.
Details
| Condition | Cardiotoxicity, Heart Failure, Dilated Cardiomyopathy |
|---|---|
| Treatment | Echocardiography with speckle tracking analysis., 48-hour ECG monitoring., Blood samples analysis. |
| Clinical Study Identifier | NCT04055636 |
| Sponsor | Moscow State University of Medicine and Dentistry |
| Last Modified on | 15 February 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer